Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (06990.HK)価格

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. engages in the research and development, manufacture, and commercialization of novel drugs. The company is headquartered in Chengdu, Sichuan and currently employs 1,870 full-time employees. The company went IPO on 2023-07-11. The firm is mainly engaged in the research and development, manufacturing and commercialization of novel drugs in oncology, immunology and other therapeutic areas. The firm's products are antibody drug conjugates (ADCs) SKB264, A166 and others. The firm's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, gastrointestinal cancer and other diseases.